A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Launched by PFIZER · Jul 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new cancer medicine called PF-08046876 to see if it is safe and how well it works in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is a special type of treatment known as an antibody drug conjugate, which means it is designed to attach directly to cancer cells and kill them while limiting harm to healthy cells. The medicine will be given through a needle into a vein, and the study will test different doses and schedules to find the best way to use it.

People who may be eligible to join are adults 18 years or older who have advanced cancer in one of the listed areas, with measurable disease, and who have tried other standard treatments that didn’t work or stopped working. Participants should be generally well enough (able to carry out daily activities) and meet certain health criteria. Those who have already been treated with similar antibody drug conjugate therapies or have certain health problems may not be able to join. If you participate, you can expect to receive the study medicine through an IV and have regular check-ups to monitor your health and how the treatment is working. This study is currently not yet recruiting but aims to help find new options for people with these difficult-to-treat cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
• • Measurable disease
• • ECOG Performance status 0-1
• • Part 1: progression or relapse following standard treatments
• • Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting
• • Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
• • Consent to submit required pre-treatment tumor tissue as medically feasible
• Exclusion criteria:
• • Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )
• • Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion
• • Pulmonary disease meeting protocol exclusion
• • Other unacceptable abnormalities as defined by protocol